Here are the Form 4 insider transactions from Amdocs Limited (DOX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DOX filings page.
Amdocs Ltd (DOX) officer Rajat Raheja reported a disposition involving 360 Restricted Stock Units through an exercise/conversion transaction on November 11, 2026. His reported position in the derivative security following the transaction was 5,503 shares.
Amdocs Ltd. (DOX) director and officer Shimie Hortig reported direct sales totaling 8,997 ordinary shares on November 10 and November 11, 2026. The transactions were 7,264 shares at $42.1763 per share on November 10, 2026, and 1,733 shares at $43.14 per share on November 11, 2026. The Rule 10b5-1 checkbox was unchecked.
Amdocs Ltd. (DOX) director Robert A. Minicucci acquired 6,058 ordinary shares in a grant/award transaction on November 9, 2026. After the transaction, his reported direct position was 311,819 ordinary shares; that figure includes ordinary shares subject to outstanding restricted stock units.
Amdocs Ltd (DOX) director Adrian Gardner acquired 6,058 ordinary shares in a reported grant or award on November 9, 2026. His reported direct position afterward was 59,580 ordinary shares; that figure includes shares subject to outstanding restricted stock units.
Amdocs Ltd. (DOX) director Yvette Kanouff reported a direct purchase of 2,400 ordinary shares at $42 per share and a separate direct grant or award acquisition of 6,058 ordinary shares on November 9, 2026. The award row reports a price of $0 per share. No Rule 10b5-1 plan is reported.
Amdocs Ltd. (DOX) director Rafael de la Vega received a grant/award of 6,058 ordinary shares on November 9, 2026. His reported direct position after the transaction was 35,894 shares, including ordinary shares subject to outstanding restricted stock units.
Amdocs Ltd. director Eliahu Meir Gelman acquired 10,810 ordinary shares in a grant on November 9, 2026. His directly held position following the award was 350,946 ordinary shares.
Amdocs Ltd. (DOX) director Amos Genish reported a direct purchase of 3,565 ordinary shares at $42 per share on November 9, 2026, plus a separate direct award acquisition of 6,058 ordinary shares that day. The purchase was not reported under a Rule 10b5-1 plan.
Amdocs Ltd (DOX) director Sarah R. Davis reported an 822-share transaction on November 9, 2026, at $42.7341 per share. The transaction is described as a purchase, but its reported direction classifies the shares as disposed. She also reported an award of 6,058 shares at $0.0000 per share. The reported share counts include Ordinary Shares subject to outstanding restricted stock units. No Rule 10b5-1 plan is reported for the 822-share transaction.
John Anthony MacDonald, a director of Amdocs Ltd. (DOX), reported two purchases of ordinary shares on November 10, 2026: 100 shares at $41.625 per share and 900 shares at $41.63 per share. The filing also reports his award acquisition of 6,058 ordinary shares on November 9, 2026. No Rule 10b5-1 plan is reported.
Amdocs Ltd. (DOX) director Veronique Morali reported a direct purchase of 134 ordinary shares at $41.31 per share on November 10, 2026; no Rule 10b5-1 plan is reported. On November 9, 2026, she reported a separate direct grant/award acquisition of 6,058 ordinary shares.
Amdocs Ltd Chief Financial Officer Tal Rozenfeld acquired 14,174 ordinary shares through a compensation-related grant/award on November 6, 2026. The reported price was 0.0000 per share. His reported direct holdings following the award were 36,917 ordinary shares; this was an award, not a market purchase.
Amdocs Ltd executive Matthew E. Smith reported an open-market sale of company stock. On this Form 4, he sold 464 Ordinary Shares of Amdocs on May 29, 2026 at an average price of $62.51 per share, for roughly $29,000 in proceeds.
After the transaction, Smith directly holds 1,550 Ordinary Shares of Amdocs. The filing reflects a routine insider sale rather than a change in compensation or option exercise, and no derivative securities are reported as remaining positions.
Hortig Shimie reported acquisition or exercise transactions in this Form 4 filing.
Amdocs Ltd director and officer Shimie Hortig received an equity grant as part of his compensation. On May 13, 2026, he was awarded 84,483 Amdocs ordinary shares at no purchase price, described as time-based restricted stock awards that vest over three years from the grant date.
After this grant, Hortig directly holds 181,696 ordinary shares. Because this is a share award rather than an open-market trade, it reflects routine equity compensation rather than a discretionary stock purchase or sale.